ArticleJournal of cancer survivorship : research and practice2025
Awareness and utilization of genetic testing for hereditary cancers in cancer survivors: a cross-sectional 2021 HINTS-SEER study.
Article in Journal of cancer survivorship : research and practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Awareness, Attitudes, and Expectations of Indian Cancer Patients and Their Caregivers on Hereditary Cancers and Genetic Testing at a Tertiary Cancer Centre in India.Journal of genetic counseling · 2026Article
- Communication With Clinicians and Relatives About Cascade Genetic Testing in Cancer Patients With Germline Pathogenic Variants.JCO precision oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
purposeWe aimed to identify factors associated with genetic testing awareness and use among a large sample of US cancer survivors participating in NCI's Health Information National Trends Survey of cancer survivors identified through the Surveillance, Epidemiology, and End Results program, a unique pilot study expanding the number of cancer survivors typically captured by HINTS.
methodsWe analyzed 2021 HINTS-SEER data to determine sociodemographic factors associated with awareness and utilization of germline genetic testing using survey-weight-adjusted multivariable logistic regression.
resultsOf 1232 survivors (any site), the majority had breast (23%) or prostate (23%) cancer. Among the overall study population, 77% were aware of and 24% utilized genetic testing. Females and those with a college education, income over $100,000, or family history of cancer had greater odds of awareness compared to males, those with less than college education, income under $20,000, or no family history, respectively. Among prostate cancer survivors, those ≥ 65 years in age had lower odds of awareness. Females and the privately insured had greater odds of utilization compared to males and publicly insured, respectively. Those ≥ 65 years or retired had lower odds of utilization compared to < 65 years and being employed, respectively.
conclusionWe identified sociodemographic factors associated with awareness and utilization of germline genetic testing among cancer survivors. Findings warrant further investigation to understand mechanisms underlying disparities in awareness and use of genetic testing. IMPLICATIONS FOR CANCER SURVIVORS: This study highlights cancer survivor populations that may require additional support around awareness of and use of germline genetic testing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.